Section Arrow
CYTK.NASDAQ
- Cytokinetics
Quotes are at least 15-min delayed:2026/02/23 08:52 EST
Pre Market
Last
 67.41
-0.53 (-0.78%)
Bid
67.41
Ask
69.9
High 67.94 
Low 66.5 
Volume 23 
Regular Hours (Closed)
Last
 --
-- (--)
Day High 
-- 
Prev. Close
67.94 
1-M High
-- 
Volume 
-- 
Bid
67.41
Ask
69.9
Day Low
-- 
Open
-- 
1-M Low
-- 
Market Cap 
8.31B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA -- 
20-SMA -- 
50-SMA -- 
52-W High -- 
52-W Low -- 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-6.30/-4.04
Enterprise Value
9.06B
Balance Sheet
Book Value Per Share
-4.26
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
18.47M
Operating Revenue Per Share
0.06
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ZYMEZymeworks-------- 
Pre Market 22.5 -0.22 -0.97%
ZVRAZevra Therapeutics-------- 
Pre Market 8.75 -0.05 -0.57%
ZURAZura Bio Limited-------- 
Pre Market 6.08 -0.12 -1.94%
ZNTLZentalis Pharmaceuticals-------- 
Pre Market 2.28 -0.14 -5.79%
ZLABZai Lab Limited-------- 
Pre Market 19.9 -0.14 -0.70%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.